ORILISSA
Live / Registered — Registered — Section 8 accepted (as of 30 Apr 2025)
What this means for you
Registered since 27 Nov 2018. The owner can stop confusingly similar uses in the classes it covers.
Record
- Serial number
- 87104202
- Registration number
- 5617902
- Mark type
- Stylized text
- Filed
- 14 Jul 2016
- Published for opposition
- 18 Oct 2016
- Registered
- 27 Nov 2018
- Attorney of record
- Sonali Srivastava
Goods and services
- Class 005 — Pharmaceuticals: pharmaceutical preparations and substances for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders
Owner
- ABBVIE LTD, HAMILTON, BM
- AbbVie Inc., North Chicago, IL, US
- AbbVie Inc., North Chicago, IL, US
- AbbVie Inc., North Chicago, IL, US
Prosecution history
- 30 Apr 2025 — NOTICE OF ACCEPTANCE OF SEC. 8 - E-MAILED
- 30 Apr 2025 — REGISTERED - SEC. 8 (6-YR) ACCEPTED
- 30 Apr 2025 — CASE ASSIGNED TO POST REGISTRATION PARALEGAL
- 18 Nov 2024 — TEAS SECTION 8 RECEIVED
- 27 Nov 2023 — COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED
- 10 Mar 2021 — AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP
- 27 Nov 2018 — REGISTERED-PRINCIPAL REGISTER
- 23 Oct 2018 — NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
- 22 Oct 2018 — ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
- 17 Oct 2018 — STATEMENT OF USE PROCESSING COMPLETE
- 20 Sept 2018 — USE AMENDMENT FILED
- 17 Oct 2018 — CASE ASSIGNED TO INTENT TO USE PARALEGAL
- 20 Sept 2018 — TEAS STATEMENT OF USE RECEIVED
- 09 Jun 2018 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 07 Jun 2018 — SOU EXTENSION 3 GRANTED